Literature DB >> 10530877

Effects of dexamethosone and glucagon after long-term exposure on cyclic AMP phosphodiesterase 4 in cultured rat hepatocytes.

T Hermsdorf1, W Richter, D Dettmer.   

Abstract

67% of total cAMP phosphodiesterase activity (PDE) in cultured rat hepatocytes could be detected in the cytosol, 15% in plasma membrane, 15% in 'dense vesicle,' and 3% in endoplasmatic reticulum fractions. Up to 84% of the PDE activity of the cytosol is represented by the rolipram-sensitive PDE 4. ICI 118233-inhibited PDE 3 was found predominantly in membranes. We were able to show that dexamethasone acts on the PDE 4 in cytosolic and plasma membrane fractions whereas glucagon effected the PDE 4 of the cytosol and the PDE 3 in 'dense vesicle' membranes. Primary culture of hepatocytes was used to study long-term effects of dexamethasone and glucagon on PDE 4 activity. Addition of dexamethasone (0.1 microM) at the beginning of cultivation leads to a decrease of total PDE 4 activity whereas after 24 h precultivation no dexamethasone effect could be observed. Glucagon effects on PDE 4 were investigated in 20 h precultured hepatocytes. Maximal stimulation was achieved after 2 h of exposure. PDE 4 subtypes A, B , D and, to a lesser degree, subtype C could be detected by RT-PCR analysis. The results of semiquantitative RT-PCR show that the presence of dexamethasone during the first 24 h of cultivation reduced selectively the transcription of PDE 4D, whereas glucagon was without any effect. Also the translation of PDE 4D was reduced as shown in the Western blot. We would like to discuss the way that dexamethasone influences PDE 4D expression-most likely in combination with other factors such as cytokines--during the time of cell plating, whereas glucagon actions are part of metabolic regulations via phosphorylation reactions.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10530877     DOI: 10.1016/s0898-6568(99)00039-x

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  7 in total

1.  A novel 3D liver organoid system for elucidation of hepatic glucose metabolism.

Authors:  Yanhua Lu; Guoliang Zhang; Chong Shen; Korkut Uygun; Martin L Yarmush; Qin Meng
Journal:  Biotechnol Bioeng       Date:  2011-10-19       Impact factor: 4.530

Review 2.  Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies.

Authors:  Adam Lerner; Paul M Epstein
Journal:  Biochem J       Date:  2006-01-01       Impact factor: 3.857

3.  Hydrocortisone normalizes oxygenation and cGMP regulation in lambs with persistent pulmonary hypertension of the newborn.

Authors:  Marta Perez; Satyan Lakshminrusimha; Stephen Wedgwood; Lyubov Czech; Sylvia F Gugino; James A Russell; Kathryn N Farrow; Robin H Steinhorn
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2011-12-23       Impact factor: 5.464

4.  Genetic variation in phosphodiesterase (PDE) 7B in chronic lymphocytic leukemia: overview of genetic variants of cyclic nucleotide PDEs in human disease.

Authors:  Ana M Peiró; Chih-Min Tang; Fiona Murray; Lingzhi Zhang; Loren M Brown; Daisy Chou; Laura Rassenti; Thomas J Kipps; Thomas A Kipps; Paul A Insel
Journal:  J Hum Genet       Date:  2011-07-28       Impact factor: 3.172

5.  Phosphodiesterase-4 inhibition with rolipram attenuates hepatocellular injury in hyperinflammation in vivo and in vitro without influencing inflammation and HO-1 expression.

Authors:  Jakob Wollborn; Christian Wunder; Jana Stix; Winfried Neuhaus; Rapahel R Bruno; Wolfgang Baar; Sven Flemming; Norbert Roewer; Nicolas Schlegel; Martin A Schick
Journal:  J Pharmacol Pharmacother       Date:  2015 Jan-Mar

6.  PDE7B is involved in nandrolone decanoate hydrolysis in liver cytosol and its transcription is up-regulated by androgens in HepG2.

Authors:  Emmanuel Strahm; Anders Rane; Lena Ekström
Journal:  Front Pharmacol       Date:  2014-05-30       Impact factor: 5.810

7.  AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B.

Authors:  M Johanns; Y-C Lai; M-F Hsu; R Jacobs; D Vertommen; J Van Sande; J E Dumont; A Woods; D Carling; L Hue; B Viollet; M Foretz; M H Rider
Journal:  Nat Commun       Date:  2016-03-08       Impact factor: 14.919

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.